Login to Your Account



Pozen Looking to Broaden ‘Horizon’ for Vimovo Sales

By Jennifer Boggs
Managing Editor

Wednesday, November 20, 2013
Shares of Pozen Inc. jumped 14.6 percent Tuesday on news that U.S. commercialization of Vimovo, its approved gastric-friendly nonsteroidal inflammatory drug, would be transferring to specialty pharma Horizon Pharma USA Inc., a company that has shown early success in marketing its own similar combo product, Duexis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription